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Recent updates in the management of Merkel Cell Carcinoma
Ahmed Nadeem Abbasi, Syed Mustajab Ahmed, Bilal Mazhar Qureshi

Abstract
M er ke l cell ca rcinoma is an a ggre ssive nonmelanomatous cutaneous tumour of neuroendocrine
origin with an increasing incidence in the recent years.
It is a tumour of the elderly and immunosuppressed,
which most often appears on sun-exposed areas of the
body. The clinical features of the cutaneous or
subcutaneous lesions hardly contribute to the diagnosis,
and, hence, histopathology and immunohistochemistry
play a vital role in diagnosis. The latest staging system
by the American Joint Committee on Cancer includes
non-nodal invasion to adjacent structures i.e. bone,
muscle, fascia, or cartilage into the criteria, in addition
to size and depth of invasion. The management relies
heavily on a multidisciplinary approach due to rarity of
incidence of this disease. According to the international
guidelines, surgical management is still the preferred
choice. The beneficial role of adjuvant radiotherapy has
now been more clearly documented. Data is insufficient
to assess whether chemotherapy improves disease-free
or overall survival.
Keywords: Carcinoma, Merkel cell, Radiotherapy, Keratin20, Keratinocytes. doi: 10.5455/JPMA.286585.

Introduction
Merkel cell carcinoma (MCC) is an aggressive nonmelanomatous cutaneous tumour of neuroendocrine
origin. It was first described in 1972 1 in a study which
observed that the tumour originates from the
neuroendocrine cells of the basal epidermis of the skin.
Later on, studies described the cell of the origin as
epidermal, non-dendritic, non-keratinocytic cell that he
referred to as a tactile cell.1 A number of other terms
have also been used to describe this pathology, such as
primary small cell carcinoma of the skin, trabecular cell
carcinoma, amine precursor uptake decarboxylase
(APUDoma) of the skin, and anaplastic cancer of the skin.
Being a rare entity, the information pertaining to clinical
diagnosis, management, and prognosis of MCC is still in
the pipeline. 2 This review is in series with previous
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reviews 1,2 providing latest updates on staging and
management of MCC.
Incidence and Demographics
Although MCC is a rare tumour, its incidence has
demonstrated an increasing trend in the past two
decades. The annual incidence of MCC in the United
States is 0.6 per 100,000. Studies from Australia and New
Zealand have documented higher incidence rates.3 The
average annual incidence between 2006 and 2010, as
reported by the Queensland cancer registry data, is 1.6
per 100,000, with a peak rate of 20.7 per 100,000 for
individuals 80 years or older.4 In addition, the annual
incidence of MCC recorded in the Netherlands increased
from 1.7 in 1993-97 to 3.5 in 2003-07. Some of the factors
which have been implicated to be the reason behind the
rise of incidence of MCC are increased awareness and
improved diagnostic techniques, especially the
introduction of cytokeratin 20 (CK20) immuno-staining.
The median age at diagnosis in women is 76.2 years
whereas that for men is 73.6 years. The incidence is rarer
in younger age groups. The incidence of MCC is
approximately 5-fold to 10-fold greater for people with
a solid organ transplant and 11-fold to 13-fold greater
in patients with acquired immunodeficiency syndrome
(AIDS), suggesting a role of immunosuppression in the
pathophysiology of MCC. The National Cancer Database
(NCDB) reports that the majority of MCC cases present
with local disease (66%), followed by nodal disease (27%),
whereas metastatic disease is an even rarer presentation
(7%). Relative survival among patients with local disease
was 64% at five years compared to 39% in regional nodal
disease and 18% in metastatic disease.3
Aetiology
Although a clear aetiology behind the occurrence of
MCC has not been defined yet, it does seem to share
natural history, clinical features and behaviour (e.g. high
recurrence rate and early spread to regional nodes) with
melanoma. 1 MCC is a tumour of the elderly and the
immunosuppressed, which most often appears on sunexposed areas of the body. In addition to
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immunosuppression and ultraviolet (UV) light exposure,
studies have been conducted focussing on the
carcinogenesis of MCC, in particular the role of Merkel
cell polyomavirus (MCPyV) and its surrogate marker large
T-antigen. Together with CK20, other biomarkers, like
human insulin gene enhancer-binding protein islet-1
(ISL1) and octamer-binding transcription factor 4 (OCT4)
may provide improved methods for diagnosis and
ultimately therapy.5 The most common site of the primary
lesion is head and neck, comprising roughly 50% of cases
(5) and other common sites are extremities (40%) and
trunk (8%).1,6
Diagnosis
The usual presentation of MCC is a painless, indurated,
solitary dermal nodule with a slightly erythematous to
deeply violaceous colour, and, less frequently, an ulcer.
In addition, the ability to infiltrate dermal lymphatics,
leading to multiple satellite lesions, is also a feature of
these lesions. However, the clinical features of the
cutaneous or subcutaneous lesions hardly contribute to
the diagnosis, and, hence, it is rarely suspected before
biopsy.7 The clinical features of MCC can be summarised
with a mnemonic asymptomatic, expanding rapidly,
immunosuppressed, older than 50 years, UV-exposed
(AEIOU) skin. 8 The initial workup for MCC includes
ultrasound of the loco-regional lymph nodes and total
body scanning examinations.7 Histopathology and an
incisional or excisional biopsy play a mandatory role in
making the diagnosis.
Histopathology
The tumour is composed of strands or nests of
monotonously uniform round blue cells, containing large
basophilic nuclei with powdery dispersed chromatin
and inconspicuous nucleoli, and minimal cytoplasm.4
Other features may include single-cell necrosis, frequent
mitoses, lymphovascular invasion, perineural invasion,
and epidermal involvement via pagetoid spread, which
can be further supported by immunohistochemical (IHC)
staining.7
Immunohistochemistry
On IHC examination, Merkel cells show features of both
epithelial and neuroendocrine cells.4 On
Immunohistochemical staining (IHC), they express
epithelial markers, such as cytokeratin AE1/AE3, CAM
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Figure-1 (A): Summarising the key points in incorporating a multidisciplinary
approach towards management of Merkel Cell Carcinoma.
Tumour

Tumour

Figure-1 (B): Summarising the key points in incorporating a multidisciplinary
approach towards management of Merkel Cell Carcinoma.
5.2, pan-cytokeratin, epithelial membrane antigen, and
Ber-EP4, and may stain for various neuroendocrine
markers, including chromogranin, synaptophysin,
somatostatin, calcitonin, and vasoactive intestinal
peptide.
The classic IHC feature of MCC which distinguishes it
f ro m ot h er u nd if fe r e nt iat e d t u mo u rs is t he
immunoreactivity for low-molecular-weight cytokeratins
(e.g., CK20, CK5/6).4 MCC consistently stains positively
for low-molecular-weight CK20, which is a fairly specific
and sensitive marker for MCC, with a characteristic
paranuclear dot-like positivity.4
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have worse survival compared to
thos e w ho are sta ged af ter
pathological examination e.g.
Sentinel lymph node biopsy
(SLNB).10,12
The staging and prognosis of MCC
has now been further updated in
the eighth edition of the tumour,
node, metastasis (TNM) staging
system, which has been
recommended by both the AJCC
and the UICC. 13 This system has
Figure-1 (C): Summarising the key points in incorporating a multidisciplinary approach towards management
been developed after an analysis
of Merkel Cell Carcinoma.
of 9387 patients with MCC from
Staging
the NCDB who were diagnosed between 1998 and 2012,
MCC can be staged according to the staging system
and it provides more detailed correlation with clinical
proposed by the American Joint Committee on Cancer
outcomes. The eighth edition provides separate criteria
(AJCC).1 Alternatively, a relatively simple system9 can be
for clinical and pathological staging in contrast to the
used for stage grouping:
former staging system. Based upon the TNM information,
Stage I: patients with localised disease; those with tumour
patients are assigned to prognostic stage groups. These
of less than 2cm are considered stage 1A, whereas those
can be summarised as follows:
with tumour of 2cm or more are considered stage 1B.
Stage I: Primary tumours 2 cm maximum tumour
Stage II: with regional lymph node metastasis.
Stage III: with distant metastasis.
At the time of first consultation, 70-80% patients with
MCC have been reported to be have stage I, 10-30%
stage II, and 4-15% stage III disease.9
Another consensus staging system was then established
in 2010 by AJCC and Union for International Cancer
Control (UICC) based on an extensive literature review
and an analysis of over 5,000 patients using the NCDB.10
This staging system defined stages I and II of MCC as
disease localised to the skin at the primary site. The
primary lesions less than or equal to 2cm were classified
as stage I, while those greater than 2cm in size were
classified as stage II. The involvement of nearby lymph
nodes (regional lymph nodes) was the criterion for
disease to be classified as stage III, whereas, stage IV
disease went beyond the regional lymph nodes. In this
system, the disease was divided into stages depending
on the severity of the disease. The chance for spread
(metastasis), treatment options, and chance for recovery
were mainly determined by the stage at the time of
diagnosis. It has been estimated that about a third of
nodal metastases are missed on clinical nodal
examination,11 and patients who staged only clinically
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dimension, without evidence of regional lymph node
involvement (Table-1).14,15
Stage II: Primary tumours >2cm (T2 or T3) or a primary
tumour with invasion into bone, muscle, fascia, or
cartilage (T4), without evidence of lymph node
involvement. Stage II is divided into two subgroups based
upon the size and depth of invasion of the primary
tumour.
Stage III: Any primary tumour with regional lymph node
disease. Pathological stage III is divided into subgroups
based upon the extent of regional lymph node
involvement (Table 2).14,15
Stage IV: Metastasis beyond the regional lymph nodes
regardless of the status of the primary tumour and
regional nodes (Tables 3-4).14,15
Table-1: Tumour, node, metastasis (TNM) staging with respect to size of primary
lesion of Merkel Cell Carcinoma according to American Joint Committee
on Cancer (AJCC) 8th edition Staging System.(14, 15).
Primary Tumour (T)
TX
T0
Tis
T1
T2
T3
T4

Primary tumour cannot be assessed (e.g., curetted)
No evidence of primary tumour
In situ primary tumour
Maximum clinical tumour diameter less than or equal to 2 cm
Maximum clinical tumour diameter >2 but less than or equal to 5 cm
Maximum clinical tumour diameter >5 cm
Primary tumour invades fascia, muscle, cartilage, or bone
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Table-2: Tumour, node and metastasis (TNM) staging with respect to clinical and
pathological nodal status of Merkel Cell Carcinoma according to American
Joint Committee on Cancer (AJCC) 8th edition Staging System. (14, 15).

Table-4: Tumour, node, metastasis (TNM) staging of Merkel Cell Carcinoma
according to American Joint Committee on Cancer (AJCC) 8th edition
Staging System.(14, 15).

Regional Lymph Nodes (N) Clinical (N)

Clinical (cTNM)
Tis
T1
T2-3
T4
T0-4
T0-4
Pathological (pTNM)
Tis
T1
T2-3
T4
T1-4
T0
T1-4
T0-4

NX

Regional lymph nodes cannot be clinically assessed (e.g., previously removed
for another reason, or because of body habitus)
N0
No regional lymph node metastasis detected on clinical and/or radiologic
examination
N1
Metastasis in regional lymph node(s)
N2
In-transit metastasis (discontinuous from primary tumour; located between
primary tumour and draining regional nodal basin, or distal to the primary
tumour) without lymph node metastasis
Pathological (pN)
pNX
Regional lymph nodes cannot be assessed (e.g., previously removed for another
reason or not removed for pathological evaluation)
pN0
No regional lymph node metastasis detected on pathological evaluation
pN1
Metastasis in regional lymph node(s)
pN1a(sn) Clinically occult regional lymph node metastasis identified only by sentinel
lymph node biopsy
pN1a Clinically occult regional lymph node metastasis following lymph node dissection
pN1b
pN2

pN3

Clinically and/or radiologically detected regional lymph node metastasis
microscopically confirmed
In-transit metastasis (discontinuous from primary tumor; located between
primary tumour and draining regional nodal basin, or distal to the primary
tumour) without lymph node metastasis
In-transit metastasis (discontinuous from primary tumour; located between
primary tumour and draining regional nodal basin, or distal to the primary
tumour) with lymph node metastasis

Table-3: Tumour, node, metastasis (TNM) staging with respect to clinical and
pathological metastases of Merkel Cell Carcinoma according to American
Joint Committee on Cancer (AJCC) 8th edition Staging System.(14, 15).
Distant Metastasis (M) Clinical (M)
M0
No distant metastasis detected on clinical and/or radiologic examination
M1
Distant metastasis detected on clinical and/or radiologic examination
M1a
Metastasis to distant skin, distant subcutaneous tissue, or distant lymph node(s)
M1b
Metastasis to lung
M1c
Metastasis to all other visceral sites
Pathological (M)
M0
No distant metastasis detected on clinical and/or radiologic examination
pM1
Distant metastasis microscopically confirmed
pM1a Metastasis to distant skin, distant subcutaneous tissue, or distant lymph node(s),
microscopically confirmed
pM1b Metastasis to lung, microscopically confirmed
pM1c Metastasis to all other distant sites, microscopically confirmed

Management
MCC is a rare tumour and due to its low incidence and
the subtlety of its presentation, its management involves
different modalities of oncological treatment. Like many
other malignancies, the management of MCC relies
mainly on a multidisciplinary approach. 16-18 After
necessary workup, including histopathological diagnosis

N0
N0
N0
N0
N1-3
Any N

M0
M0
M0
M0
M0
M1

0
I
IIA
IIB
III
IV

N0
N0
N0
N0
N1a(sn) or N1a
N1b
N1b-3
Any N

M0
M0
M0
M0
M0
M0
M0
M1

0
I
IIA
IIB
IIIA
IIIA
IIIB
IV

and relevant staging workup, each case should be
discussed in a multidisciplinary tumour board to reach
a decision on further management. 16 The current
recommendations are in favour of surgical intervention
being the main course of treatment,19 but the scarcity
of prospective trials investigating this modality is a major
factor contributing to the variability of opinion among
clinicians. The guidelines for the management of MCC,
therefore, explore all approaches i.e. surger y,
chemotherapy and radiotherapy (RT).
Surgery
In order to address the problem of high risk of recurrence
of MCC, it has been recommended that the entire lesion
be excised at the time of initial presentation to achieve
clear surgical margins whenever feasible, keeping in
mind that any planned adjuvant RT should not get
significantly delayed. The clinical size of the primary
lesion plays an important role in the management. For
primary tumours without evidence of organ metastases,
excision with 1cm margins for tumours <2cm in size and
2cm margins for those >2cm in size has been
recommended (Figure 1-A). 20 The size of the safety
margins may need to be decreased in cases with head
and neck involvement to increase aesthetic and
functional outcomes.18,21 In terms of surgical approach,
Mohs micrographic surgery (MMS) has been widely used
as a treatment for MCC and has been shown to be as
effective as wide local excision (WLE) in treating localised
MCC,22 although the need for concurrent sentinel node
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mapping (and/or neck dissection) suggests that WLE of
the primary tumour in the same setting could be a better
choice in certain circumstances.20 A coordinated surgical
management is warranted in all cases, so that sentinel
lymph node biopsy could be performed prior to definitive
surgical intervention, as lymphatic drainage is prone to
be altered otherwise. 14,15 The role of SLNB in the
management of MCC has been reflected in a review of
161 MCC patients which found that SLNB identified
micro-metastases in one-third of patients.23 It has been
documented by National Comprehensive Cancer
Network (NCCN) panel that identifying patients with
nodal disease and subsequently performing nodal
dissection and/or RT, enhances the regional control.7,14
However, it should be kept in consideration that SLNB
may be less reliable in head and neck compared to trunk
and body.14,15
After verification of clear margins and performing SLNB,
if indicated, reconstruction should be performed as soon
as possible after surgery. Maximising the efforts to
m inimis e t he ex ten siv e t issu e mo ve me nt in
reconstruction and the delay in adjuvant radiation (if
p la nne d) is re lat ed to b et te r o u tco m e s. 1 4 , 1 5
Radiation Treatment
The rationale of offering RT in the management of MCC
has been under debate for a long time. There is relatively
little documentation available identifying patients with
MCC who have received RT in adjuvant setting (less than
200 published). A study reviewed the Memorial SloanKettering Cancer Centre's MCC database and identified
251 patients who had been treated between 1970 and
2002.24 It analysed patient, tumour, and treatment-related
factors for their association with recurrence and survival,
but no association was found between irradiation and
loco-regional control.25
The weight of evidence now is in favour of considering
adjuvant RT for patients with MCC.20,26-28 Adjuvant RT
has been advocated in order to control local as well as
regional disease.26-28 A systemic review suggests that
definitive RT for loco-regional macroscopic MCC provides
clinically meaningful local and regional control.29 A metaanalysis comparing the role of surgery alone versus
surgery with adjuvant RT demonstrated that the use of
adjuvant RT significantly reduced the risk of local and
regional recurrence. Adjuvant RT might be considered
in patients with multiple affected lymph nodes of
extracapsular extension.7

Vol. 69, No. 11, November 2019

1697
After complete resection of the tumour, the primary
disease site must be observed if the tumour is small
(<1cm), widely excised, and without other risk factors
i.e. lymphovascular invasion or immunosuppression.
Radiation-induced toxicity should be considered and
discussed with the patient. According to the guidelines
formulated by the National Comprehensive Cancer
Network, a dose of 50-56Gy should be delivered if the
resected margins are clear of the disease, whereas in
cases with microscopically positive resection margins,
56-60Gy should be delivered. In case of grossly positive
resection margins, or failure to undergo surgery due to
unresectability, patient refusal, or significant morbidity,
a dose of 60-66Gy should be delivered to the primary
site (Figure 1-B).14,15
Regarding the draining nodal sites, 60-66Gy is
recommended for clinically evident lymphadenopathy
if the patient has not undergone SLNB or lymph node
(LN) dissection, whereas 46-50Gy should be delivered if
there is risk of subclinical nodal disease in a clinically
node-negative patient in the same setting. For patients
who undergo SLNB with negative results, adjuvant RT
after surgery is not recommended. However, 50-56Gy
should be delivered for SLNB-proven nodal disease. In
cases of multiple nodes and/or extracapsular extension,
50-60Gy should be administered after LN dissection
(Figure 1-C).14,15
RT has also been under consideration in the management
of in-transit metastases (stage IIIB) of MCC as it is not
possible to contain the disease and ensure clear margins
with surgical approach only.30,31 Hence, the role of RT
has acquired vital importance in this regard. RT to the
primary site and satellite lesions with a 3-5cm margin
with 50Gy in 25 fractions,31 avoiding interruptions has
been recommended, with additional boost to the gross
disease (10-16Gy) using electrons.30 This
recommendation can be supported by literature that RT
can achieve more than 75% in-field control rates. 32
Compared to surgery, dermal lypmhatics canbe widely
covered using RT. In addition, RT poses fewer late effects
t ha n su rg e r y- p lu s- R T, e sp e c ia ll y t he r i sk o f
lymphoedema.32
Previously, RT has been shown to improve survival in
tumours of all sizes, but in current literature, the greatest
impact on survival has been in cases where tumours
were >2 cm.20 Data is conflicting as to whether there is
any survival benefit from adjuvant primary site or
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regional nodal irradiation, partly due to the lack of
prospective clinical trials.33 The only randomised control
trial to date comparing excision with RT versus excision
w it h obser vation showed no overa ll sur vival
improvement with adjuvant RT, but showed a significant
reduction in regional recurrence.6
Chemotherapy
The effect of adjuvant radiation on survival is currently
unproven, but the benefit of chemotherapy seems to
be more clearly lacking and should not be recommended
routinely. 33 Chemotherapy is usually reserved for
systemic disease, though the success of this treatment
is limited, and no chemotherapy protocol has been
shown to improve survival.20 Although chemotherapy
has been used with or without surgery and/or RT for
stage IV i.e. cases with distant metastases (M1), it is also
being considered for selected cases of macroscopic
regional disease (N1b or N2). For local disease, adjuvant
chemotherapy is not recommended.14,15
Nonetheless, data is insufficient to assess whether
chemotherapy improves disease-free or overall survival
in MCC patients with distant metastases. The most
commonly used regimen used is cisplatin or carboplatin
with or without etoposide. Topotecan is also considered
in some cases of older patients. A regimen comprising
cyclophosphamide, doxorubicin and vincristine is
commonly considered, but it is associated with significant
toxicity. Despite what has been stated, clinicians should
exercise evidence-based and patient-centred judgment
i n c ho os in g c h e m o t h e r a p e u t i c re g im en . 1 4 , 1 5
Hyper-thermic isolated limb perfusion
Although not included in practice guidelines,
hyperthermic isolated limb perfusion has been shown
to confer some clinical benefits in the management of
MCC. A retrospective review suggests that regional
perfusion is safe and has a high complete response rate
in a selected group of patients, providing durable locoregional control of the disease. 34 A multicentre study
evaluating the efficacy of isolated limb perfusion in
which combination therapy with melphalan and tumour
necrosis factor (TNF) was utilised demonstrated an overall
response rate (ORR) of 87.5% with a complete response
(CR) rate of 62.5%. Median loco-regional progressionfree survival (LPFS) was 5 months and median overall
survival was 54 months.35

Conclusion
Putting all facts in the equation, features which are
important in the management of MCC are the rarity of
incidence, nonspecific clinical history, and aggressive
nature leading to early loco-regional spread, distant
metastases and high relapse rates. These features
together make MCC a challenge for the team of treating
clinicians. Consequently, it is imperative that each case
be discussed in a multidisciplinary expert-panel tumour
board before embarking on the first treatment modality.
The deficiency of literature on MCC to help construct
evidence-based management guidelines for clinicians
warrants the need for conducting prospective clinical
trials.
Disclaimer: None.
Conflict Of Interest: None.
Source of Funding: None.
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